Viamet Pharmaceuticals Appoints Richard Katz, M.D. as Chief Business and Financial Officer

Published: Mar 07, 2012

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc., a world leader in the development of “best-in-class” therapies targeting key metalloenzymes, announced today the appointment of Richard D. Katz, M.D. to the newly-created position of Chief Business and Financial Officer. Dr. Katz will be responsible for strategic planning and direction, overseeing commercial and financial operations and execution of the Company’s corporate and business development activities.

Back to news